RadNet Inc. Common Stock (RDNT) fair value

ACCE thesis

RadNet runs outpatient diagnostic imaging centers across the US, selling MRI, CT, mammography and ultrasound scans, with a growing digital health arm that sells AI-assisted breast cancer screening and workflow software to radiology practices. The structural case rests on imaging volumes that keep rising as an aging population and wider screening guidelines push demand toward outpatient settings, where costs are lower than hospitals. Revenue growth of 25.0% is the headline number, and the forward P/E of 36.6 shows the market is paying up for that growth, though the 7.9% operating margin and 1.5% ROE show how little of it has reached shareholders so far. What we would need to see before spending more time is operating leverage: whether the digital segment and same-center volumes can lift margins while the company works down its debt-heavy balance sheet. At a 46 score the name clears the bar for a closer look at the cash flow statement, not for a position.